09:50 AM EST - Isotechnika Pharma Inc. : announced today that it has reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for its planned phase 3 clinical trial of its lead product candidate, voclosporin. The SPA is a written agreement with the FDA that the phase 3 clinical study design, endpoints, statistical analyses, and other aspects of the planned study are acceptable to support marketing approval. Isotechnika Pharma Inc.
shares T.ISA are trading even at $0.13.
